 SAN FRANCISCO, Sept. 09, 2021 GLOBE NEWSWIRE -- Olema Pharmaceuticals, Inc. Olema or Olema Oncology, Nasdaq: OLMA, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced a poster presentation of new preclinical data on OP-1250, a complete estrogen receptor ER antagonist CERAN and a selective ER degrader SERD being developed for the treatment of metastatic breast cancer and other womens cancers, at the 1st JCA-AACR Precision Cancer Medicine International Conference being held virtually from September 10-12, 2021 U.S. and September 11-12 Japan. 